Pfizer and BioNTech To Initiate COVID-19 Vaccine Clinical Trials In April
Executive Summary
The two companies announced more details about their COVID-19 vaccine development plan, including a $185m upfront payment and $113m equity investment from Pfizer.
You may also be interested in...
Pfizer Rose To The COVID-19 Challenge And The Stars Aligned
Pfizer moved aggressively and early as COVID-19 became a global health threat, and now the company, with its partner BioNTech, is the first to secure an emergency use authorization for a COVID vaccine from the US FDA.
Pfizer Rose To The COVID-19 Challenge And The Stars Aligned
Pfizer moved aggressively and early as COVID-19 became a global health threat, and now the company, with its partner BioNTech, is the first to secure an emergency use authorization for a COVID vaccine from the US FDA.
An Ambitious COVID-19 Vaccine Development Plan For Pfizer And BioNtech
Pfizer said it is dosing patients now with an mRNA-based vaccine and expects human data in May/June, with a goal to have a vaccine available for emergency use possibly by October.